Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
21 Marzo 2023 - 5:00AM
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology
company dedicated to discovering and developing transformative
treatments to restore and improve hearing and balance, today
announced the appointment of Matthew Kapusta to its Board of
Directors.
“We are pleased to welcome Matt to the Decibel Board. He is an
accomplished life sciences executive who has played a key role in
advancing gene therapy products from the laboratory to patients in
need,” said Laurence Reid, Ph.D., Chief Executive Officer at
Decibel. “Matt’s appointment to the Board provides us with a
critical strategic perspective, as we continue to build Decibel and
lead the way in applying the power of gene therapy to conditions of
the inner ear.”
Matthew Kapusta has 25 years of experience in the life sciences
industry and currently serves as Chief Executive Officer and
Director of uniQure, a global gene therapy company. Under his
leadership, uniQure successfully developed the world’s first
approved gene therapy for people living with hemophilia B. Prior to
joining uniQure, Mr. Kapusta held executive roles at AngioDynamics
and Smith & Nephew. Mr. Kapusta’s career also includes more
than a decade of investment banking experience where he focused on
mergers, acquisitions and corporate finance transactions for
emerging life sciences companies. Mr. Kapusta holds a Master of
Business Administration from New York University’s Stern School of
Business and a Bachelor of Business Administration from University
of Michigan’s Ross School of Business, and he previously earned a
Certified Public Accountant license in 1996 while at Ernst &
Young.
“I am thrilled to join Decibel’s Board at this exciting
juncture, as the company prepares to evaluate its first gene
therapy product candidate in the clinic. Laurence has assembled a
talented management team and I’ve been impressed with Decibel’s
focus and scientific prowess as it advances a number of programs,”
said Mr. Kapusta. “Gene therapy holds enormous promise to help
address unmet medical needs, and I’m excited to be on board as
Decibel applies this transformational modality to hearing and
balance disorders.”
About Decibel TherapeuticsDecibel Therapeutics
is a clinical-stage biotechnology company dedicated to discovering
and developing transformative treatments to restore and improve
hearing and balance, one of the largest areas of unmet need in
medicine. Decibel has built a proprietary platform that integrates
single-cell genomics and bioinformatic analyses, precision gene
therapy technologies and expertise in inner ear biology. Decibel is
leveraging its platform to advance gene therapies designed to
selectively replace genes for the treatment of congenital,
monogenic hearing loss and to regenerate inner ear hair cells for
the treatment of acquired hearing and balance disorders. Decibel’s
pipeline, including its lead gene therapy product candidate,
DB-OTO, to treat congenital, monogenic hearing loss, is designed to
deliver on our vision of creating a world of connection for people
with hearing and balance disorders. For more information about
Decibel Therapeutics, please visit www.decibeltx.com or follow us
on Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, contained in this press
release, including statements regarding Decibel’s strategy, future
operations, prospects, plans, objectives of management, the
therapeutic potential for Decibel’s product candidates and
preclinical programs, and the potential benefits of cell-selective
expression constitute forward-looking statements within the meaning
of The Private Securities Litigation Reform Act of 1995. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “might,” “objective,” “ongoing,” “plan,”
“predict,” “project,” “potential,” “should,” or “would,” or the
negative of these terms, or other comparable terminology are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Decibel
may not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not
place undue reliance on these forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in these forward-looking
statements as a result of various important factors, including:
uncertainties inherent in the identification and development of
product candidates, including the timing of and Decibel’s ability
to obtain approval to initiate clinical development of its program
candidates, whether results from preclinical studies will be
predictive of the results of later preclinical studies and clinical
trials, whether Decibel’s cash resources are sufficient to fund its
foreseeable and unforeseeable operating expenses and capital
expenditure requirements, uncertainties related to the impact of
the COVID-19 pandemic on Decibel’s business and operations, as well
as the risks and uncertainties identified in Decibel’s filings with
the Securities and Exchange Commission (SEC), including those risks
detailed under the caption “Risk Factors” in Decibel’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2022 and
in other filings Decibel may make with the SEC. In addition, the
forward-looking statements included in this press release represent
Decibel’s views as of the date of this press release. Decibel
anticipates that subsequent events and developments will cause its
views to change. However, while Decibel may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Decibel’s views as of any date subsequent to the date
of this press release.Investor Contact:Julie
SeidelStern Investor Relations,
Inc.julie.seidel@sternir.com212-362-1200
Media Contact:Chris RaileyTen Bridge
CommunicationsChris@tenbridgecommunications.com617-834-0936
Decibel Therapeutics (NASDAQ:DBTX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Decibel Therapeutics (NASDAQ:DBTX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024